JP2015517470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517470A5 JP2015517470A5 JP2015510508A JP2015510508A JP2015517470A5 JP 2015517470 A5 JP2015517470 A5 JP 2015517470A5 JP 2015510508 A JP2015510508 A JP 2015510508A JP 2015510508 A JP2015510508 A JP 2015510508A JP 2015517470 A5 JP2015517470 A5 JP 2015517470A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- seq
- acid sequence
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 230000001965 increasing effect Effects 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 14
- 102000004127 Cytokines Human genes 0.000 claims description 14
- 210000003289 regulatory T cell Anatomy 0.000 claims description 13
- 230000006052 T cell proliferation Effects 0.000 claims description 10
- 201000005962 mycosis fungoides Diseases 0.000 claims description 10
- 229960005486 vaccine Drugs 0.000 claims description 10
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 8
- 230000028327 secretion Effects 0.000 claims description 7
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 108700012439 CA9 Proteins 0.000 claims description 6
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 4
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 4
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 4
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 230000016396 cytokine production Effects 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 101000738584 Homo sapiens C-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000009359 Sezary Syndrome Diseases 0.000 claims description 2
- 208000021388 Sezary disease Diseases 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 229960001212 bacterial vaccine Drugs 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 102000043444 human CCR4 Human genes 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229960004854 viral vaccine Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642749P | 2012-05-04 | 2012-05-04 | |
| US61/642,749 | 2012-05-04 | ||
| US201361785559P | 2013-03-14 | 2013-03-14 | |
| US61/785,559 | 2013-03-14 | ||
| PCT/US2013/039744 WO2013166500A1 (en) | 2012-05-04 | 2013-05-06 | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018120054A Division JP6704954B2 (ja) | 2012-05-04 | 2018-06-25 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517470A JP2015517470A (ja) | 2015-06-22 |
| JP2015517470A5 true JP2015517470A5 (OSRAM) | 2016-06-23 |
| JP6411329B2 JP6411329B2 (ja) | 2018-10-24 |
Family
ID=48428719
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510508A Active JP6411329B2 (ja) | 2012-05-04 | 2013-05-06 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2018120054A Active JP6704954B2 (ja) | 2012-05-04 | 2018-06-25 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2020084311A Pending JP2020127426A (ja) | 2012-05-04 | 2020-05-13 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2022086515A Withdrawn JP2022119907A (ja) | 2012-05-04 | 2022-05-27 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018120054A Active JP6704954B2 (ja) | 2012-05-04 | 2018-06-25 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2020084311A Pending JP2020127426A (ja) | 2012-05-04 | 2020-05-13 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
| JP2022086515A Withdrawn JP2022119907A (ja) | 2012-05-04 | 2022-05-27 | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9441045B2 (OSRAM) |
| EP (2) | EP2844674A1 (OSRAM) |
| JP (4) | JP6411329B2 (OSRAM) |
| AU (1) | AU2013256010B2 (OSRAM) |
| CA (1) | CA2871751C (OSRAM) |
| HK (1) | HK1207655A1 (OSRAM) |
| WO (1) | WO2013166500A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2585004B2 (ja) | 1987-07-15 | 1997-02-26 | 太洋鋳機株式会社 | 連続式混練機における自動清掃装置 |
| AU2013256010B2 (en) * | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| EP3054975A4 (en) * | 2013-10-11 | 2017-06-28 | Sloan-Kettering Institute for Cancer Research | Methods and compositions for regulatory t-cell ablation |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JP6795505B2 (ja) * | 2014-10-06 | 2020-12-02 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
| CN108064252A (zh) | 2014-12-19 | 2018-05-22 | 达纳－法伯癌症研究所公司 | 嵌合抗原受体及其使用方法 |
| KR20170138556A (ko) * | 2015-05-01 | 2017-12-15 | 다나-파버 캔서 인스티튜트 인크. | 항ccr4 항체를 이용하여 사이토카인 발현을 매개하는 방법 |
| HRP20231156T1 (hr) | 2015-12-22 | 2024-01-05 | Regeneron Pharmaceuticals, Inc. | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US11077178B2 (en) | 2016-09-21 | 2021-08-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use |
| WO2018071913A2 (en) | 2016-10-14 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Modular tetrameric bispecific antibody platform |
| IL268479B2 (en) | 2017-02-21 | 2024-06-01 | Regeneron Pharma | Anti-PD-1 antibodies for the treatment of lung cancer |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JP2021502345A (ja) | 2017-11-06 | 2021-01-28 | ラプト・セラピューティクス・インコーポレイテッド | 抗がん剤 |
| CN108250290B (zh) | 2018-02-23 | 2024-03-12 | 上海捌加壹医药科技有限公司 | Ccr4的n端重组蛋白及其用途 |
| EP3765070A4 (en) | 2018-03-14 | 2021-12-15 | Dana-Farber Cancer Institute, Inc. | SPECIFICALLY MODIFIED CELLS, T-LYMPHOCYTE IMMUNE MODULATION ANTIBODIES AND THEIR USE PROCEDURES |
| MX2021000290A (es) * | 2018-07-11 | 2021-09-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente dirigidos a ccr4. |
| US12448462B2 (en) | 2019-06-14 | 2025-10-21 | Dana-Farber Cancer Institute, Inc. | Antibodies against MUC1 |
| CN113388640B (zh) * | 2020-06-11 | 2022-12-20 | 百奥赛图(北京)医药科技股份有限公司 | Ccr4基因人源化的非人动物及其构建方法和应用 |
| WO2022117572A2 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | An ltbr agonist in combination therapy against cancer |
| WO2024163530A2 (en) * | 2023-02-01 | 2024-08-08 | Crown Bioscience Inc. | Novel anti-ccr4 antibodies and derivative products |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| KR100252547B1 (ko) | 1991-09-05 | 2000-09-01 | 프레드 마리얀스키 | 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달 |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| WO1995022618A1 (en) | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| AU2013256010B2 (en) * | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
-
2013
- 2013-05-06 AU AU2013256010A patent/AU2013256010B2/en active Active
- 2013-05-06 CA CA2871751A patent/CA2871751C/en active Active
- 2013-05-06 EP EP13722266.7A patent/EP2844674A1/en not_active Ceased
- 2013-05-06 HK HK15108293.0A patent/HK1207655A1/xx unknown
- 2013-05-06 US US14/398,910 patent/US9441045B2/en active Active
- 2013-05-06 WO PCT/US2013/039744 patent/WO2013166500A1/en not_active Ceased
- 2013-05-06 EP EP18209618.0A patent/EP3511343A1/en active Pending
- 2013-05-06 JP JP2015510508A patent/JP6411329B2/ja active Active
-
2015
- 2015-08-07 US US14/820,882 patent/US9587028B2/en active Active
-
2017
- 2017-01-27 US US15/418,510 patent/US20180094064A1/en not_active Abandoned
-
2018
- 2018-06-25 JP JP2018120054A patent/JP6704954B2/ja active Active
- 2018-12-17 US US16/222,342 patent/US20190276544A1/en not_active Abandoned
-
2020
- 2020-05-13 JP JP2020084311A patent/JP2020127426A/ja active Pending
-
2022
- 2022-05-27 JP JP2022086515A patent/JP2022119907A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517470A5 (OSRAM) | ||
| JP2020127426A5 (OSRAM) | ||
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| JP2015535691A5 (OSRAM) | ||
| JP2022159548A5 (OSRAM) | ||
| JP2017531427A5 (OSRAM) | ||
| JP2020193210A5 (OSRAM) | ||
| JP2013502913A5 (OSRAM) | ||
| ES2887299T3 (es) | Cadena J modificada | |
| JP2024105296A5 (OSRAM) | ||
| JP2019513777A5 (OSRAM) | ||
| JP2013227339A5 (OSRAM) | ||
| JP2020103301A5 (OSRAM) | ||
| JP2017537972A5 (OSRAM) | ||
| JP2020525032A5 (OSRAM) | ||
| JP2017506067A5 (OSRAM) | ||
| JP2021508255A5 (OSRAM) | ||
| JP2014076062A5 (OSRAM) | ||
| JP2019536430A5 (OSRAM) | ||
| US20240199750A1 (en) | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging | |
| JP2015502138A5 (OSRAM) | ||
| JP2018502060A5 (OSRAM) | ||
| JP2017522043A5 (OSRAM) | ||
| JP2020515247A5 (OSRAM) | ||
| JP2020500523A5 (OSRAM) |